(NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, and Degeneration ...

Exudation, and Degeneration 2025 virtual meeting on February 8, 2025 and the BIO CEO & Investor Conference being held on February 10-11, 2025 at the New York Marriott Marquis in New York City.

This review describes clinical features, diagnosis and role of various antifungal agents in FE and the management and outcome of species-specific fungal endophthalmitis. Voriconazole Triazole ...

Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target ...

Methods Medical records were reviewed for all patients with acute-onset endophthalmitis after cataract surgery from January 2006 to December 2011 at eight eye centres of tertiary care hospitals in ...